Skip to main content

Advertisement

Table 4 Baseline fasting biochemistry for the 9795 randomized participants in the FIELD study

From: Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

Parameter Baseline After 6 weeks of fenofibrate||
Mean SD Median Q1, Q3 Mean SD
Total cholesterol (mmol/L) 5.04* 0.69 5.03* 4.56, 5.54 4.49 0.69
HDL cholesterol (mmol/L)¶ 1.10* 0.26 1.06* 0.92, 1.24 1.16 0.29
Calculated LDL cholesterol (mmol/L) 3.07* 0.64 3.08* 2.62, 3.51 2.71 0.62
Triglycerides (mmol/L) 1.94* 0.88 1.74* 1.34, 2.34 1.37 0.63
Total-to-HDL cholesterol ratio 4.81* 1.10 4.71* 4.04, 5.49 4.08 1.13
Apolipoprotein B (g/L) 0.97* 0.17 0.97* 0.86, 1.09 0.83 0.18
Creatinine (mmol/L) 0.08† 0.02 0.08† 0.07, 0.09 0.09 0.02
Fibrinogen (g/L) 3.6† 0.8 3.6† 3.1, 4.1 3.12 0.75
Fasting glucose (mmol/L) 8.9† 2.6 8.5† 7.0, 10.3 -- --
Urinary albumin-to-creatinine ratio (mg/mmol) 5.9† 21.8 1.2† 0.7, 3.0 -- --
Homocysteine (μmol/L) 10.2§ 3.7 9.5§ 7.9, 11.6 -- --
Insulin (mU/L) 15.7‡ 24.0 12.0‡ 8.0, 18.5 -- --
HbA1c (%) 7.1† 1.4 6.9† 6.1, 7.8 -- --
  1. * Average of Visit 2 and Visit 3.
  2. † Average of Visit 1 and Visit 3.
  3. ‡ Visit 1 only.
  4. § Visit 3 only.
  5. ¶ Baseline HDLc (mean ± SD): men = 1.03 ± 0.23 mmol/L, women = 1.21 ± 0.28 mmol/L
  6. || All changes at six weeks were statistically significant at P < 0.0001
  7. -- not measured